Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG<sub>2</sub> Monoclonal Antibody, in Healthy Volunteers.

Mathur, Mohit; Barratt, Jonathan; Suzuki, Yusuke; Engler, Frank; Pasetti, Marcela F; Yarbrough, Jill; Sloan, Susan; Oldach, David

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG₂ Monoclonal Antibody, in Healthy Volunteers.

Mathur, Mohit; Barratt, Jonathan; Suzuki, Yusuke; Engler, Frank; Pasetti, Marcela F; Yarbrough, Jill; Sloan, Susan; Oldach, David.

Afiliação

Mathur M; Visterra, Inc., Waltham, Massachusetts, USA.
Barratt J; John Walls Renal Unit, Leicester General Hospital, Leicester, UK.
Suzuki Y; Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Engler F; Certara USA, Inc., Princeton, New Jersey, USA.
Pasetti MF; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Yarbrough J; Visterra, Inc., Waltham, Massachusetts, USA.
Sloan S; Visterra, Inc., Waltham, Massachusetts, USA.
Oldach D; Visterra, Inc., Waltham, Massachusetts, USA.

Kidney Int Rep ; 7(5): 993-1003, 2022 May.

Article em En | MEDLINE | ID: mdl-35570983

Palavras-chave

APRIL; IgA nephropathy; clinical trial; galactose-deficient IgA; glomerulonephritis; monoclonal antibody

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Kidney Int Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google